Responses
Clinical/translational cancer immunotherapy
Original research
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
